DB16654InvestigationalProtein Based Therapies
Nivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor...
- Mechanism
- Curator reviewed
Pharmacologically active on GD2 disialoganglioside and T-cell surface glycoprotein CD3
- Also known as
- Hu3F8-BsAb
Resolves to
Compound
What you can answer from here — as of July 08, 2026
Which companies are running trials of Nivatrotamab, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account